ABSTRACT OBJECTIVE: Ketoconazole (KCZ) is an anti-fungal agent extensively used for clinical applications related to its inhibitory effects on adrenal and testicular steroidogenesis. Much less information is available on the effects of KCZ on synthesis of steroid hormones in the ovary. The present study aimed to characterize the in situ effects of KCZ on steroidogenic enzymes in primary rat ovary cells.
Introduction
Ketoconazole, (KCZ, Nizoral®) is an anti-mycotic imidazole drug known to inhibit the activity of several steroidogenic enzymes. As such, the drug has been clinically exploited in the last decades to suppress steroidogenesis in conditions like Cushing's syndrome, prostate cancer, precocious puberty, and hirsutism. [1] [2] [3] [4] Therefore, it is not surprising that the drug's effects on the adrenal and testis were thoroughly investigated. [5] [6] [7] In contrast, there are fewer studies on the effects of KCZ on ovarian steroidogenesis and its potential effects related to fertility treatments. For example, we and others have previously found that administration of a low dose of KCZ to polycystic ovarian syndrome patients during superovulation attenuated ovarian folliculogenesis 8, 9 and better controlled the hyperstimulated response to gonadotropins. 8 In addition, KCZ was also shown to improve clomiphene responsiveness in PCOS patients. 10 In view of the potentially beneficial use of KCZ in reproduction, several studies attempted to analyze the biochemical basis for the drug effect on the ovary. 8, [11] [12] [13] [14] [15] [16] [17] [18] However, the use of multiple experimental models yielded incomplete and occasionally contradictory information that led us to seek a model CliniCal MediCine insights: RepRoduCtive health 2014:8 3βHSD1, 5a-reductase, 3a-HSD, and 17HSD1 activity assays. Granulosa cells were prepared from prepubertal rat, 44 hours after administration of eCG. KCZ (10 mg/mL) was added 30 minutes prior to adding 1 mM [ 3 H]-pregnenolone (3βHSD1 assay) or 1 mM [ 3 H]-estrone (17HSD1 assay), and further incubated for two and six minutes, respectively. To assay 17HSD1, we preferred to use estrone as androstenedione is rapidly converted to 5a-androstanedione (data not shown) by the high prepubertal ovarian 5a-reductase.
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CYP17A1/P450c17 (17a-hydroxylase and 17,20 lyase) activity assays. Whole ovarian cell suspension was prepared from prepubertal rat examined 24 hours after eCG (ie, FSH + LH) administration. Owing to the rapid metabolism of [ 3 H]-progesterone to pregnanolone, we assessed the effect of KCZ on the dual activities of CYP17A1/P450c17, using [ 3 H]-pregnanolone as substrate added following a preincubation (30 minutes) with KCZ (0.1-10 mg/mL, 2.5 × 10 5 cells). For assay of the 17,20 lyase cellular activity, cells as above were incubated for 10 minutes with [ 3 H]-17a-hydroxyprogesterone substrate; excessive androstenedione (50 mM) was added five minutes prior to the addition of the radioactive substrate. Cells treated with KCZ (10 mg/mL) underwent preincubation as above.
CYP19A1/P450arom activity assay. Granulosa cells were prepared from prepubertal rat, 44 hours after administration of eCG. CYP19A1 activity was determined by measuring the stereospecific release of tritium to produce 3 H 2 O when [1β,2β-3 H]-testosterone (0.25 mM, 1.5 × 10 5 cpm in 300 mL medium and 2.5 × 10 5 cells) is aromatized to 17β-estradiol. 23, 24 After four hours, the cell suspension was transferred into plastic RIA tubes for quantification of aromatization dependent release of 3 H 2 O as previously described. 23, 24 Steroid metabolism. Assay of [ 3 H]-steroid metabolism was assessed using 5-8 × 10 5 cells incubated in 500 mL of DMEM/F-12 (1:1) medium containing KCZ added 30 minutes prior to the addition of the steroid tracer. At the indicated time points, 100-200 mL aliquots of the cell suspension were withdrawn into 500 mL diethylether for extraction and TLC analysis of the [ 3 H]-steroids metabolites.
Results Figure 1 depicts the steroidogenic pathways previously characterized by us and others in cells of the immature rat ovary. 19, 25, 26 Following the key step catalysis of cholesterol conversion to pregnenolone by CYP11A1, we used the 3βHSD1 product, progesterone, for further analysis of three potential pathways: first, progesterone can be substrate for the activity of 5a-reductase (Fig. 1c ) yielding pregnanolone; this pathway prevails in the immature rat ovarian cells. 19, 22 Second, the 20a-HSD activity (Fig. 1j ) transforms progesterone to the much less active 20a-OHP in granulosa-lutein cells. 27 Third, in this ovarian cell model, the slow activity rate of CYP17A1 does not allow the demonstration of progesterone processing to androgens hence, this enzyme activity can be providing a complete view of the drug effects on the entire ovarian steroidogenic enzymatic cascade starting from cholesterol down to estradiol synthesis. To this aim, we used freshly prepared ovarian cells from either immature rats or females induced to ovulate by gonadotropin administration. Freshly isolated cells were then incubated with different steroid substrates and the effect of KCZ was assessed on each of the enzymatic activities.
Materials and Methods
Hormones, radiochemicals, and reagents. Pregnant mare serum gonadotropins (Equine Chorionic Gonadotropin; eCG; Gestyl) and human chorionic gonadotropin (hCG; Pregnyl) were purchased from Organon (Oss, Holland Ovarian steroidogenic pathways and effects of KCZ. This figure describes the steroidogenic pathways in the ovary and summarizes the results of KCZ effects on enzymatic activities. each enzymatic reaction is marked by a letter in the order of its evaluation and description in the Results section. thick horizontal lines indicate inhibitory loci of KCZ. the authentic steroid names denote the generic equivalent as following: 20a-hydroxy-4-pregnen-3-one (20a-hydroxyprogesterone; 20a-ohp); 20a-hydroxy-5a-pregnan-3-one (20a-oh-pregnanone); 5a-pregnane-3a,20a-diol (pregnanediol); 5a-pregnane-3,20-dione (pregnanedione); 3a-hydroxy-5a-pregnan-20-one (pregnanolone); 17a-hydroxyprogesterone (17a-ohp); 17a-hydroxy5a-pregnane-3,20-dione (17a-oh-pregnanedione); 3a,17a-dihydroxy-5a-pregnan-20-one (dihydroxypregnanone); 5a-androstane-3,17-dione (androstanedione); androst-4-ene-3,17-dione (androstenedione); dihydrotestosterone (dht); 5a-androstane-3a,17β-diol (androstanediol). enzymes in order of their evaluation are denoted as following: CYP11A1 (side-chain cleavage of P450; P450scc), 3βHSD1 (3β-hydroxysteroid dehydrogenase-Δ isomerase type 1), 20a-steroid dehydrogenase (20a-hsd); 3a-steroid dehydrogenase (3a-hsd); CYp17a1 (17a-hydroxylase/17,20 lyase; p450c17), CYP19A1 (aromatase; P450arom), and 17HSD1 (17β-hydroxysteroid dehydrogenase type 1). measured once pregnanolone is fed as substrate (Fig. 1e-g ). 22 Aromatization of androgens carried by CYP19A1/P450arom in gonadotropin-primed granulosa cells can be assessed upon addition of testosterone substrate (Fig. 1m) . Finally, we also assessed the activity of 17HSD1 normally required for conversion of estrone to 17β-estradiol (Fig. 1n) .
CYP11A1. The effect of KCZ on CYP11A1 activity was assessed in granulosa-lutein cells showing a dose dependent inhibition of hydroxycholesterol conversion to pregnenolone (KCZ IC 50 = 0.3 mg/mL) (Fig. 2) . In the absence of KCZ, pregnenolone accumulation was evident because of the presence of cyanoketone mediated inhibition of 3βHSD1.
3b HSD1, 5a-reductase, and 3a-HSD. To determine the conversion of pregnenolone to other progestins initiated by 3βHSD1 (Figs. 3b-d) , we examined granulosa cells expressed in eCG primed prepubertal animals, which are highly steroidogenic in follicles approaching their first ovulatory LH surge. Figure 3 shows that KCZ did not affect the 3βHSD1 activity consuming 95% of the 3 H-pregnenolone in 6 minute incubation. As expected, the terminal steroid metabolite, pregnanolone, accumulates because of the high 5a-reductase [ 3 H]-17a-OHP toward the 5a-reductase pathway, we added excessive unlabeled androstenedione (50 mM). In the absence of KCZ, as well as in presence of the drug, close to 60% of the [ 3 H]-17a-OHP substrate was converted to androstenedione (Fig. 6B ) suggesting no inhibition of 17,20 lyase by KCZ. Collectively, these results suggest that KCZ inhibits only the first of the dual catalytic reactions of CYP17A1.
CYP19A1. KCZ inhibited (IC 50 = 0.3 mg/mL) the conversion of testosterone to 17β-estradiol in granulosa cells retrieved from eCG-treated rat ovary (Fig. 7m) .
17HSD1. Estrone was preferred as the substrate for the assessment of the effect of KCZ on 17HSD1 (Materials and Methods section) showing that KCZ has no effect on this enzyme activity (Fig. 8) .
Reversibility of KCZ effect. To examine whether KCZ inhibition is reversible, CYP17A1 was the enzyme of choice because of its fast activity rate among the P450s. To this aim, [ 3 H]-pregnanolone was fed to a whole ovarian cell suspension. Figure 9A shows that within 60 minutes, over 60% of substrate was converted to the enzyme products (Figs. 9e-g ). A complete inhibition of the latter was observed in the presence of KCZ (Fig. 9B) , which could be fully reversed 30 minutes after the cells were washed free of the drug (Fig. 9B'' ).
Discussion
To obtain a comprehensive dissection of KCZ effects on the steroid biosynthetic pathways in the ovary, we followed the metabolic fate of radiolabeled steroid precursors in and 3a-HSD activities in the prepubertal rat ovary. 22 KCZ did not inhibit the latter two enzymes.
20a-HSD. In order to investigate the conversion of [ 3 H]-progesterone by 20a-HSD (Fig. 4j) we used luteal cells from eCG-treated rats 22 hours after hCG administration, which are inherently devoid of CYP17A1/P450c17. Moreover, subsequent to the first ovulation, the 5a-reductase activity is substantially attenuated, while the activity of 20a-HSD is markedly increased. 28 Figure 4 demonstrates that KCZ does not affect the 20a-HSD activity. Residual conversion of 20a-OHP to pregnanediol, via a low reductase and 3a-HSD activities, corroborate that KCZ does not affect those noncytochrome enzymes.
CYP17A1. Incubation of whole ovarian cell preparation with progesterone as CYP17A1 substrate and KCZ inhibited the cytochrome activity. However, the accumulation of pregnanolone corroborated the predominance of the 5a-reductase pathway over that of 17a-hydroxylase (Figs. 5c-i) . The absolute KCZ inhibition of androsterone and androstanediol production (Figs. 5f,g ) provided further support in favor of this pathway.
To directly determine the IC 50 value for KCZ inhibition of CYP17A1, [ 3 H]-pregnanolone was purified from ovarian cell cultures and used as substrate. Figure 6A shows that KCZ inhibited the metabolism of pregnanolone with an apparent IC 50 of 1.8 mg/mL. However, since it was not clear which of the two inherent CYP17A1 activities was affected by KCZ, we added [
3 H]-17a-OHP as immediate substrate for the 17,20 lyase activity (Fig. 6B) . To prevent loss of the intact cells. This was our method of choice because freshly prepared cells better reflect the physiological characteristics of the ovarian response to KCZ, including the uptake of the drug into the cells, its intracellular metabolism, and the subsequent inhibition of the steroidogenic enzymes. Using this experimental model, the results clearly show that KCZ inhibits dose-dependently and selectively the rat ovarian CYP11A1, 17a-hydroxylase activity of CYP17A1, and CYP19A1. In contrast, the five non-P450 enzymes and the 17,20 lyase activity of CYP17A1 were not inhibited by as much as 10 mg/mL of KCZ. This is the first report showing a direct inhibitory effect of KCZ on CYP11A1 catalysis in the ovary. The observed IC 50 value (0.3 mg/mL; 0.56 mM) for KCZ action on CYP11A1 of rat ovarian cells is in good agreement with previously reported values obtained in isolated cells of rat adrenal (0.3 mg/mL), 29 cell-free preparations of rat adrenal and testis, 7, 30 and mitochondrial enriched fractions of human placenta (0.3 mM).
31
It is well known that similar to the other steroidogenic P450s, CYP17A1 performs a two-step catalysis consisting of substrate hydroxylation followed by cleavage of a carboncarbon bond. 32 Clearly, KCZ inhibited the 17a-hydroxylase activity (IC 50 ~ 1.8 mg/mL) and thus corroborates earlier findings in rat testicular tissue, 33 Leydig cells preparations from human, stallion, and pig testes, 34 as well as in rat and human testicular homogenates. 35, 36 Moreover, in the present ovarian cell model KCZ did not inhibit the 17,20 lyase activity of CYP17A1. Thus, the selective KCZ-mediated inhibition of 17a-hydroxylase is valuable in light of the apparent inconsistencies observed in other studies using different models of testicular origin, including minced tissue pieces, 33, 37 isolated Leydig cells, 34 cell-free assays, 31, 35, 36 or even different use of CYP17A1 substrates. 38 In ovarian models, the effect of KCZ on the dual activities of CYP17A1 was never assessed before in a defined cell model. For example, KCZ inhibition of microsomal 17a-hydroxylase prepared from whole ovary homogenate was reported using very high concentrations (50-5000 mM) 16 previously found toxic in our hands. 8 Others concluded that KCZ inhibits the 17,20 lyase activity of CYP17A1 by incubating pieces of human ovary, 18 or preparing ovarian microsomes from rats orally pretreated with KCZ (4 mg/day). 13 As expected, KCZ also inhibited the activity of the third steroidogenic cytochrome P450, CYP19A1 (IC 50 = 0.3 mg/mL; 0.56 mM) in the rat granulosa cells. Thus, except for one study, 16 our results corroborate previously reported findings by others. [12] [13] [14] [15] 17, 18, 39, 40 While reviewing previous studies on the effect of KCZ on the non-P450 steroidogenic enzymes, one can note inconsistent findings depending on the experimental model. Similar to our results, studies using intact cell models observed lack of KCZ effect on 3β-HSD and 17β-HSD 7, 8, 33, 36 while the use of cell-free preparations yielded inhibitory effects of the drug at exceedingly high concentrations. 16 Similarly, we could not detect any effect of KCZ on 5a-reductase, 3a-HSD, and 20a-HSD.
Several studies have previously argued for the preferential inhibitory effect of KCZ on the gonadal CYP17A1. For example, KCZ decreased intratesticular testosterone production by inhibiting both 17a-hydroxylase and 17,20 lyase activities, following oral pretreatment with the drug in men with prostate cancer who underwent orchiectomy. 36 Similarly, a relatively stronger inhibitory effect of KCZ was shown for the CYP17A1 activity in Leydig cells from human, stallion, and pig testes. 34 In contrast, this report using a defined cell model did not reveal IC 50 differences in KCZ effects on the rat ovarian cytochromes P450s.
In conclusion, the results of the present study support the notion that KCZ is a selective and effective inhibitor of the ovarian P450 enzymes. The comprehensive analysis of the KCZ effect on the ovarian steroidogenic pathways may assist in the development of selective drugs applied in clinical situations requiring acute, yet reversible suppression of ovarian steroidogenesis related to rapidly growing ovarian cysts, induction of ovulation, and ovarian hyperstimulation syndrome.
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